Biotech Values

[mcbio]

EnVivo Pharmaceuticals Announces Statistically Significant Improvement in Cognition and Clinical Function in Phase 2b Clinical Trial in Alzheimer’s Disease

I see that EnVivo is private but, among publicly-traded small-cap biotechs, I know that TRGT is also working on an alpha-7 agonist (http://www.targacept.com/wt/page/tc_5619 ). TRGT is running Phase 2 trials in ADHD and schizophrenia, with the former set to report 2H this year and they say they are evaluating a Phase 2 trial in Alzheimer's. Perhaps these results will compel them to run such a trial. I haven't been much of a fan of TRGT but shares have been battered and you have to wonder if there could be some salvage value given the news for EnVivo and the fact that TRGT is involved in this space as well.

Here are links to the prior Phase 2a results for TC-5619 in schizophrenia and ADHD: http://www.targacept.com/wt/page/pr_1302179429 and http://www.targacept.com/wt/page/pr_1300969304 respectively. The schizophrenia results seem promising though AZN decided against licensing the drug after these results and it remains wholly-owned by TRGT right now.